Calithera Biosciences Inc. (NASDAQ:CALA) shares saw unusually-strong trading volume on Friday . Approximately 551,192 shares traded hands during mid-day trading, an increase of 86% from the previous session’s volume of 295,608 shares.The stock last traded at $3.40 and had previously closed at $3.44.

Several equities research analysts have recently commented on CALA shares. Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Tuesday, March 22nd. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a report on Wednesday, June 8th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a report on Thursday, May 12th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.48.

The firm’s market capitalization is $65.02 million. The stock’s 50 day moving average is $4.36 and its 200 day moving average is $5.26.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.05. On average, analysts expect that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.